For the second time this year, pharma company AFT Pharmaceuticals (ASX: AFP) has bagged the US Food and Drug Administration’s (FDA) approval. In March 2023, it was approved for Maxigesic Rapid, a rapid-release tablet for acute pain. This time, it’s for Maxigesic IV, the intravenous form of its patented pain relief medicine. The approval was
Read More
Maxigesic’s tagline goes: Put it to the test for your pain. Its maker—pharma company AFT Pharmaceuticals (ASX: AFP) —did indeed put the med to the test, and it came out as a winner, bagging FDA’s approval. Sort of like a super tablet, Maxigesic combines the powers of ibuprofen and paracetamol to create a super powerful
Read More
Sticks and stones may break my bones but words may result in legal action because they can be misconstrued despite conscious wording. Luckily for AFT Pharmaceuticals (ASX: AFP) the Australian High Court has sided with them, dismissing complaints made by the makers of Nurofen, Reckitt-Benckiser around the advertising of AFT’s painkiller product, Maxigesic. Just yesterday
Read More
Fresh off their recent distribution success of their intravenous, non-opioid based pain medication, AFT Pharmaceuticals (ASX: AFP) has ticked another box announcing the receival of regulatory approval for another form of the drug. The oral liquid form of Maxigesic is a non-opioid based analgesic and extension of AFT’s patented Maxigesic family of medications. The oral
Read More
Pain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a
Read More